Dr. Jordan answers the question: 'How can I be estrogen receptor-positive?' — -- Question: How can my breast cancer be estrogen receptor-positive when I am postmenopausal and my body is losing ...

Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for giredestrant, an investigational oral ...

The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...

A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common ...

Retrospective Study to Determine Factors Influencing Outcome in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Neoadjuvant Chemotherapy Women with ...

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery This open-label, parallel-group trial randomly assigned 132 participants to receive camizestrant 75, 150, or 300 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...

Human epidermal growth factor receptor 2 (HER2) proteins are found on the surface of breast cells and are involved in normal cell growth. Too much HER2 protein, however, can cause some types of breast ...